Daratumumab, an Original Approach for Treating Multi-refractory Autoimmune Cytopenia

Overview

Journal Haematologica

Specialty Hematology

Date 2021 Aug 5

PMID 34348453

Citations 15

Authors

Etienne Crickx

Sylvain Audia

Ailsa Robbins

David Boutboul

Thibault Comont

Morgane Cheminant

Eric Oksenhendler

Bertrand Godeau

Marc Michel

Matthieu Mahevas

Affiliations

Soon will be listed here.

Citing Articles

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report.

Zoubi I, Warwar A, Perek S, Preis M Immunotargets Ther. 2025; 14():1-5.

PMID: 39802214 PMC: 11721704. DOI: 10.2147/ITT.S487895.

Immune thrombocytopenia in patients with systemic lupus erythematosus.

Zheng Z, Liu J, Yun M, Deng L, Xiang P, Jiang M Clin Rheumatol. 2024; 44(1):97-104.

PMID: 39627479 DOI: 10.1007/s10067-024-07235-5.

Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.

Pilon C, Joher N, Usureau C, Boutin E, Boueilh A, Taupin J Kidney Int Rep. 2024; 9(11):3250-3264.

PMID: 39534185 PMC: 11551132. DOI: 10.1016/j.ekir.2024.08.020.

Autoimmune haemolytic anaemias.

Michel M, Crickx E, Fattizzo B, Barcellini W Nat Rev Dis Primers. 2024; 10(1):82.

PMID: 39487134 DOI: 10.1038/s41572-024-00566-2.

[Chinese expert consensus on the diagnosis and treatment of Evans syndrome (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024; 45(9):809-815.

PMID: 39414602 PMC: 11518912. DOI: 10.3760/cma.j.cn121090-20240506-00171.

References

Driouk L, Schmitt R, Peters A, Heine S, Girschick H, Strahm B . Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature. Mol Cell Pediatr. 2021; 8(1):5. PMC: 8085143. DOI: 10.1186/s40348-021-00114-y. View

Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A . Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol. 2019; 187(2):e48-e51. DOI: 10.1111/bjh.16171. View

Cooling L, Hugan S . Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. Transfusion. 2019; 59(12):3801-3802. DOI: 10.1111/trf.15539. View

Ostendorf L, Burns M, Durek P, Heinz G, Heinrich F, Garantziotis P . Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2020; 383(12):1149-1155. DOI: 10.1056/NEJMoa2023325. View

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

Zaninoni A, Giannotta J, Galli A, Artuso R, Bianchi P, Malcovati L . The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol. 2021; 12:649441. PMC: 7956980. DOI: 10.3389/fimmu.2021.649441. View

Michel M, Terriou L, Roudot-Thoraval F, Hamidou M, Ebbo M, Le Guenno G . A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2016; 92(1):23-27. DOI: 10.1002/ajh.24570. View

Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M . Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018; 2(19):2550-2553. PMC: 6177653. DOI: 10.1182/bloodadvances.2018020883. View

Even-Or E, Eddin A, Shadur B, Schejter Y, Najajreh M, Zelig O . Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2019; 67(1):e28010. DOI: 10.1002/pbc.28010. View

10.

Audia S, Mahevas M, Samson M, Godeau B, Bonnotte B . Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017; 16(6):620-632. DOI: 10.1016/j.autrev.2017.04.012. View

11.

Dossier C, Prim B, Moreau C, Kwon T, Maisin A, Nathanson S . A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. 2020; 36(5):1175-1182. PMC: 7594934. DOI: 10.1007/s00467-020-04811-0. View

12.

Lonial S, Weiss B, Usmani S, Singhal S, Chari A, Bahlis N . Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027):1551-1560. DOI: 10.1016/S0140-6736(15)01120-4. View

13.

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E . Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014; 124(19):2930-6. DOI: 10.1182/blood-2014-06-583021. View

14.

Mahevas M, Gerfaud-Valentin M, Moulis G, Terriou L, Audia S, Guenin S . Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016; 128(12):1625-30. DOI: 10.1182/blood-2016-03-704734. View

15.

Jain A, Gupta D . Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol. 2020; 100(5):1351-1353. DOI: 10.1007/s00277-020-04063-w. View